Search

Voyager Therapeutics Inc

Slēgts

3.5 4.17

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.43

Max

3.5

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

-24M

Pārdošana

572K

3.2M

EPS

-0.4

Peļņas marža

-773.239

Darbinieki

141

EBITDA

4.4M

-23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+327.35% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 9. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

31M

213M

Iepriekšējā atvēršanas cena

-0.67

Iepriekšējā slēgšanas cena

3.5

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. sept. 23:51 UTC

Core PPI Release on September 10 Expected to Show 0.3% Increase Amid Strong Employment Data and Speculation of Fed Rate Hikes Due to Inflation Concerns.

2026. g. 5. sept. 23:41 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% in August Amid Strong Job Growth and Heightened Interest Rate Hike Speculation

2026. g. 5. sept. 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid ECB Tightening and Investor Caution Ahead of September Release

2026. g. 5. sept. 23:01 UTC

Australia's Consumer Confidence Set for Release Amid Mixed Economic Signals and Global Uncertainties

2026. g. 5. sept. 22:51 UTC

Mexico's Inflation Rate Release on September 9, 2026, Sparks Market Concerns Amid Strong U.S. Jobs Data and Potential Interest Rate Adjustments.

2026. g. 5. sept. 22:51 UTC

Mexico's August 2026 Inflation Rate Release Expected to Influence Monetary Policy and Investor Confidence Amid Easing Trends.

2026. g. 5. sept. 22:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid positive market trends and strong U.S. job growth influencing economic outlook.

2026. g. 5. sept. 22:41 UTC

U.S. MBA 30-Year Mortgage Rate Set to Rise Amid Strong Job Growth and Inflation Concerns, Influencing Fed Interest Rate Expectations

2026. g. 5. sept. 22:31 UTC

Brazil's Central Bank readout on interest rates set for September 8, 2026, amid global economic influences and heightened speculation in financial markets.

2026. g. 5. sept. 22:21 UTC

Japan's Q2 2026 GDP Growth Forecast at 1.1% Amid Concerns Over Sharp Decline in Household Spending

2026. g. 5. sept. 22:21 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.4% Amid Mixed Economic Signals and Volatile Markets

2026. g. 5. sept. 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Concerns and Global Market Influences Ahead of September Decision.

2026. g. 5. sept. 22:11 UTC

UK Housing Market Sentiment Remains Negative as RICS House Price Balance Forecasts Slight Improvement Amid Broader Economic Concerns

2026. g. 5. sept. 21:51 UTC

South Korea's Unemployment Rate Release on September 8, 2026, Expected Amid Global Job Growth Optimism Following Strong U.S. Data

2026. g. 5. sept. 21:31 UTC

Cautious Market Sentiment Ahead of BRC Retail Sales Monitor YoY Release, Forecasting 1.2% Growth Amid Mixed Economic Signals

2026. g. 5. sept. 21:21 UTC

Spain's Consumer Confidence Index set for release on September 8, with analysts hopeful for improvement amid geopolitical tensions and inflation concerns.

2026. g. 5. sept. 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Trends.

2026. g. 5. sept. 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Recovery Signals.

2026. g. 5. sept. 20:41 UTC

Japan's Current Account Surplus Forecasted at JPY 2,870 Billion Amid Cautious Sentiment from Declining Household Spending

2026. g. 5. sept. 19:21 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Anticipated Amid Geopolitical Tensions and Recent Inventory Volatility.

2026. g. 5. sept. 19:11 UTC

Italy's Industrial Production MoM data for July 2026 set to release on September 10, with a forecasted increase of only 0.3% amid declining trends and mixed signals from Europe.

2026. g. 5. sept. 19:01 UTC

Correlated Moves

Cardano is rising during Saturday's session, supported by Ethereum's performance. The asset is trading above its 20-day moving average, reflecting strong momentum.

2026. g. 5. sept. 18:31 UTC

Swiss Consumer Confidence Index Expected to Remain Low at -32.0 Amidst Cautious Market Sentiment and Global Economic Concerns

2026. g. 5. sept. 18:11 UTC

EUR/SEK is trading roughly flat in after-market hours, showing little change since Friday's close and remaining near the upper end of its one-month range.

2026. g. 5. sept. 18:11 UTC

EUR/CAD is trading roughly flat in after-market hours, showing little change from Friday's close and remaining near the lower end of its one-month range.

2026. g. 5. sept. 18:11 UTC

Turkey's Industrial Production YoY data release on September 10, 2026, may reflect cautious optimism amid recent fluctuations and mixed market sentiment.

2026. g. 5. sept. 17:41 UTC

U.S. Monthly Budget Statement on September 11, 2026, expected to reveal rising deficits amid cautious fiscal sentiment and potential Fed interest rate decisions.

2026. g. 5. sept. 17:41 UTC

France's Industrial Production Expected to Rise 0.3% Amid Cautious Economic Sentiment and Construction Sector Decline

2026. g. 5. sept. 17:31 UTC

UK's Non-EU Goods Trade Balance Report Set for Release on September 11, 2026 Amidst Stable Market Sentiment.

2026. g. 5. sept. 17:31 UTC

UK Monthly GDP Expected to Remain Flat at 0.0% for July Amid Cautious Investor Sentiment and Mixed Economic Signals

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

327.35% augšup

Prognoze 12 mēnešiem

Vidējais 15 USD  327.35%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

4

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
help-icon Live chat